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Objective: To describe the characteristics and prognosis of patients with COPD admitted to 
the hospital due to SARS-CoV-2 infection.
Methods: The SEMI-COVID registry is an ongoing retrospective cohort comprising con-
secutive COVID-19 patients hospitalized in Spain since the beginning of the pandemic in 
March 2020. Data on demographics, clinical characteristics, comorbidities, laboratory tests, 
radiology, treatment, and progress are collected. Patients with COPD were selected and 
compared to patients without COPD. Factors associated with a poor prognosis were analyzed.
Results: Of the 10,420 patients included in the SEMI-COVID registry as of May 21, 2020, 
746 (7.16%) had a diagnosis of COPD. Patients with COPD are older than those without 
COPD (77 years vs 68 years) and more frequently male. They have more comorbidities 
(hypertension, hyperlipidemia, diabetes mellitus, atrial fibrillation, heart failure, ischemic 
heart disease, peripheral vascular disease, kidney failure) and a higher Charlson Comorbidity 
Index (2 vs 1, p<0.001). The mortality rate in COPD patients was 38.3% compared to 19.2% 
in patients without COPD (p<0.001). Male sex, a history of hypertension, heart failure, 
moderate–severe chronic kidney disease, presence of cerebrovascular disease with sequelae, 
degenerative neurological disease, dementia, functional dependence, and a higher Charlson 
Comorbidity Index have been associated with increased mortality due to COVID-19 in 
COPD patients. Survival was higher among patients with COPD who were treated with 
hydroxychloroquine (87.1% vs 74.9%, p<0.001) and with macrolides (57.9% vs 50%, 
p<0.037). Neither prone positioning nor non-invasive mechanical ventilation, high-flow 
nasal cannula, or invasive mechanical ventilation were associated with a better prognosis.
Conclusion: COPD patients admitted to the hospital with SARS-CoV-2 infection have more 
severe disease and a worse prognosis than non-COPD patients.
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Introduction
In December 2019, cases of pneumonia caused by a new strain of coronavirus, 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were described in 
Wuhan, China. This was the origin of the COVID-19 pandemic declared by the 
World Health Organization (WHO).
Chronic obstructive pulmonary disease (COPD) is defined as the presence of 
persistent respiratory symptoms and limitation of air flow due to abnormalities of 
the airway and/or alveolar airways. It is often caused by significant exposure to 
harmful particles and gases. It is known that these patients have high comorbidity 
and that a hospital admission implies a deterioration in their quality of life and 
greater morbidity and mortality.1,2
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Comorbidities are considered risk factors for SARS- 
CoV-2 infection and are associated with greater severity of 
the disease and a worse prognosis. Patients with COPD 
have been classified as an at-risk population.3,4
SARS-CoV-2 spike (S) protein binds angiotensin con-
verting enzyme 2 (ACE2) and together with host trans-
membrane serine protease 2 (TMPRSS2) promotes cell 
entry. The expression of ACE2 and TMPRSS2 has been 
identified in lung type II pneumocytes, ileal absorptive 
enterocytes, and nasal goblet secretory cells. Increased 
expression of genes related to ACE2 and CD147 has 
been described in asthma, COPD, hypertension, smoking, 
obesity, and male gender status. This may predispose 
individuals to an increased risk of coronavirus respiratory 
tract infections in active smokers and virus-related exacer-
bations in patients with COPD.5–7
In mice, ACE2 and angiotensin II receptor type 2 
(AT2) have been shown to protect them from severe 
acute lung injury induced by acid aspiration or sepsis, 
whereas ACE, angiotensin II and the angiotensin II type 
1a receptor (AT1a) induces lung oedema and impair lung 
function. The same authors show that ACE-deficient mice 
show milder disease and that recombinant ACE2 can pro-
tect them from severe acute lung injury.8
The altered expression of these receptors could contri-
bute to the patterns of morbidity and severity of 
COVID-19.
Two reviews have been published on this issue. In the 
first review, which is one of 11 general case series that aim 
to assess the prevalence of severe COVID-19 in patients 
with COPD who are smokers, concluded that COPD and 
a history of active smoking implied a worse prognosis.9 In 
the second review regarding COPD patients with COVID- 
19, the risk of severe disease (63%) and mortality (60%) 
was high, indicating that these patients have an increased 
risk of serious complications and death.10
In order to better manage patients with COPD who 
require hospitalization due to SARS-CoV-2 infection, we 
must know the predisposing factors, observe the clinical 
presentation, provide guidelines on appropriate treatment, 
and monitor their progress and prognosis in order to pro-
vide them with the best therapeutic management.
In Spain, at least half of COPD patients are hospita-
lized in internal medicine departments. Furthermore, the 
majority of patients hospitalized for SARS-CoV-2 are 
cared for in internal medicine units. This makes the col-
lection of information from these departments feasible.11
The aim of this work is to analyze the characteristics 
and prognosis of COPD patients admitted to the hospital 
due to SARS-CoV-2 infection.
Materials and Methods
Observational Study
The SEMI-COVID-19 registry is an ongoing retrospective 
cohort comprising consecutive patients hospitalized in 150 
hospitals in Spain from March 2020 with confirmed 
COVID-19 disease who died during hospitalization or 
were discharged.12 Inclusion began on March 27 and is 
still ongoing. A complete list of the SEMI-COVID-19 
Network members is provided in the Appendix.
All consecutive patients with confirmed SARS-CoV-2 
infection who were discharged after hospitalization or who 
died were eligible for inclusion in the registry. COVID-19 
disease was confirmed either by a positive result on real- 
time polymerase chain reaction (RT-PCR) testing of 
a nasopharyngeal or sputum sample or by a positive result 
on serological testing and a clinically compatible presenta-
tion. Inclusion criteria for the registry were: a) patient age 
≥ 18 years, b) a confirmed diagnosis of COVID-19, c) first 
hospital admission in a Spanish hospital participating in 
the registry, d) hospital discharge or in-hospital death.
Patients were treated at their attending physician´s dis-
cretion, according to local protocols and clinical judgment.
The data is retrospectively collected from medical 
records by clinical researchers from across the country. 
Data are collected on almost 300 variables, grouped into 
several sections: (1) inclusion criteria; (2) epidemiological 
data; (3) RT-PCR and serology; (4) personal history and 
previous medication; (5) symptoms and physical examina-
tion upon admission; (6) laboratory tests (arterial blood 
gas, biochemical analysis, complete blood count, coagula-
tion) and imaging on admission; (7) additional data seven 
days after admission or admission to an intensive care 
unit; (8) pharmacological treatment during admission 
(antivirals, immunomodulators, antibiotics) and ventilatory 
support; (9) complications during hospitalization, and (10) 
evolution after discharge and/or 30 days after diagnosis. 
The variables in the registry have been described 
previously.12
An online electronic data capture system (DCS) has 
been developed. The DCS includes a database administra-
tor and a set of procedures for data verification. Patients 
are de-identified in the registry, identifiable data are dis-
sociated and pseudonymised using an alphanumeric code. 
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Each investigator maintains a protected patient registry in 
order to verify data and control quality. The database 
platform is hosted on a secure server, both the database 
and each client-server transfer being encrypted. The pseu-
donymisation system allows patient privacy to be 
respected while complying with ethical considerations 
and data protection regulations.
The Spanish Society of Internal Medicine (SEMI) is 
the promoter of this study. The investigators who coordi-
nate the study in each hospital are partners of SEMI and 
agreed to participate in the study voluntarily and without 
any remuneration. The monitoring of the study is carried 
out by the scientific committee of the same and an inde-
pendent agency. Logistical coordination and data analysis 
are also carried out by independent agencies.
For this work, the patients included in the SEMI- 
COVID-19 Registry who had the diagnosis of COPD 
recorded in their medical history as a personal history 
were selected, without the obligation to have a diagnostic 
spirometry. In those who had a spirometry reflected in 
their clinical history, the percentage value of FEV1 was 
collected.
The variables selected for analysis included demo-
graphic variables (age, sex, obesity, smoking, comorbid-
ities, degree of dependence and use of inhaled or oral 
corticosteroids, antivitamin K drugs, antiplatelets, statins, 
ACE inhibitors, Angiotensin-renin blockers); clinical vari-
ables on admission (signs and symptoms, laboratory results 
and radiological findings); treatment received on admission 
(beta-lactams, macrolides, quinolones, hydroxychloro-
quine, lopinavir/ritonavir, remdesivir, systemic corticoster-
oids, immunoglobulins, beta interferon, tocilizumab or 
anakinra); radiological evolution, ventilatory support (inva-
sive and non-invasive mechanical ventilation and high-flow 
oxygen therapy) and clinical results (admission to the ICU 
and death).
Data on patients with COPD were selected and com-
pared to data on non-COPD patents. Factors indicating 
poor prognosis were analyzed, defined as all-cause mor-
tality. All-cause mortality during hospitalization was the 
primary endpoint.
For the subsequent data analysis, the STATA statistical 
system was used.
Qualitative variables are expressed as absolute fre-
quency (n) and percentage (%). Quantitative variables are 
expressed as median, interquartile range, and range with 
a 95% confidence interval. Qualitative variables were 
compared using the chi-square test. Continuous variables 
were compared using the Mann–Whitney test and logistic 
regression of variables. Statistical significance was defined 
as a p value <0.05.
Ethical Aspects
Personal data is processed in strict compliance with Law 14/ 
2007, of July 3, on Biomedical Research; Regulation (EU) 
2016/679 of the European Parliament and of the Council, of 
April 27, 2016, on the protection of natural persons with 
regard to the processing of personal data and the free circu-
lation of said data, and by which repeals Directive 95/46/EC 
(General Data Protection Regulation); and Organic Law 3/ 
2018, of December 5, on the Protection of Personal Data 
and Guarantee of Digital Rights. The SEMI-COVID-19 
Registry was first approved by the Provincial Research 
Ethics Committee of Malaga (Spain), following the recom-
mendation of the Spanish Agency for Medicines and Health 
Products (AEMPS). Informed consent was requested from 
the patients. When it was not possible to obtain it in writing 
for biosafety reasons or because the patient was already 
discharged from hospital, verbal informed consent was 
requested and entered in the medical record.
Results
Of a total of 10,420 patients included in the SEMI-COVID-19 
registry as of May 21, 2020, 746 (7.16%) had a history of 
COPD. Tables 1 and 2 showed the characteristics of non- 
COPD and COPD patients. The data indicated that COPD 
patients were older than patients without COPD (77 years vs 
68 years) and were more likely to be male (82.2% vs 54.7%). 
They had more comorbidities, especially cardiovascular 
comorbidities (hypertension, hyperlipidemia, diabetes melli-
tus, atrial fibrillation, heart failure, ischemic heart disease, 
peripheral vascular disease, renal failure); a higher Charlson 
Comorbidity Index and age-corrected Charlson Comorbidity 
Index (3 vs 6, p<0.001); and had greater functional depen-
dence. FEV1 was recorded for 364 patients with COPD, with 
a mean FEV1 of 59%.
The percentage of patients with COPD who were trea-
ted with systemic corticosteroids was 7.4% and the per-
centage treated with inhaled corticosteroids was 47.2%. 
Patients with COPD were also more likely to had been 
taking antiplatelet drugs, anticoagulants, statins, ACE inhi-
bitors, and angiotensin-renin blockers.
In patients with COPD, the clinical presentation of 
COVID-19 usually involved low-grade fever, dyspnea, 
and expectoration, with fewer non-respiratory symptoms 
than non-COPD patients. On examination, these patients 
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were more likely to present with hypoxemia, tachypnea, 
and confusional symptoms, with the presence of rhonchi 
and wheezing on pulmonary auscultation.
All-cause mortality in COPD patients was 38.3%, com-
pared to 19.2% in non-COPD patients (p<0.001). Male sex, 
a history of hypertension, heart failure, moderate–severe 
chronic kidney disease, the presence of cerebrovascular 
disease with sequelae, degenerative neurological disease, 
dementia, functional dependence, and a higher Charlson 
Comorbidity Index had been associated with higher mortal-
ity in COPD patients (Tables 3 and 4). The relationship was 
nearly significant in patients with a history of myocardial 
Table 1 Characteristics of People with Coronavirus Disease 2019 with or without COPD. Demographic Data and Comorbidity
Characteristics Values are Indicated as the Number (Percentage) or Median (Interquartile Range)
Overall (n=10,420) N (%) Non-COPD (n=9674) COPD (n=746) P value
Median (IQR) age (years) 10,385 69 (55–79) 68 (54–79) 77 (71–84) -
Age (years):
<45 years 10,385 1130 (10.9) 1130 (11.7) 0 (0.0) -
45–55 years 1325 (12.8) 1316 (13.7) 9 (1.2) <0.001
55–65 years 1884 (18.1) 1798 (18.7) 86 (11.6) <0.001
65–75 years 2258 (21.7) 2049 (21.3) 209 (28.1) 0.596
75–85 years 2263 (21.8) 1973 (20.5) 290 (39) 0.004
>85 years 1525 (14.7) 1376 (14.3) 149 (20.0) omitted
Men 10,401 5893 (56.7) 5281 (54.7) 612 (82.2) <0.001
Smoking status
Never 9904 6890 (69.6) 6783 (74) 107 (14.7) -
Former 2482 (25.0) 1968 (21.4) 514 (70.7) <0.001
Current 532 (5.4) 426 (4.6) 106 (14.6) 0.46
Alcohol use disorder 10,112 470 (4.7) 384 (4.0) 86 (11.8) <0.001
Obesity (BMI>30) 4597 1537 (33.4) 1415 (33.6) 122 (32.1) 0.57
Hypertension 10,404 5242 (50.4) 4729 (48.9) 513 (69.1) <0.001
Hyperlipidemia 10,401 4078 (39.2) 3682 (38.1) 396 (53.4) <0.001
Diabetes Mellitus 10,379 1936 (18.7) 1745 (18.1) 191 (25.8) <0.001
Anxiety disorder 10,377 842 (8.1) 779 (8.0) 63 (8.5) 0.71
Depression 10,376 1092 (10.5) 1014 (10.5) 78 (10.5) 0.99
Atrial fibrillation 10,395 1175 (11.3) 1000 (10.4) 175 (23.6) <0.001
Myocardial infarction 10,410 619 (5.6) 521 (5.4) 98 (13.2) <0.001
Heart failure 10,406 775 (7.5) 643 (6.7) 132 (17.8) <0.001
Transient ischemic attack 10,377 747 (7.2) 657 (6.8) 90 (12.2) <0.001
Dementia 10,403 1066 (10.3) 987 (10.2) 79 (10.6) 0.74
Neurodegenerative disease 10,401 979 (9.4) 908 (9.4) 71 (9.5) 0.89
Peripheral arterial disease 10,397 503 (4.8) 414 (4.3) 89 (12.0) <0.001
Mild chronic liver disease 10,393 294 (2.8) 255 (2.6) 39 (5.2) <0.001
Moderate–severe chronic liver disease 10,401 110 (1.0) 90 (0.9) 20 (2.7) <0.001
Chronic kidney disease 10,399 631 (6.1) 549 (5.7) 82 (11.0) <0.001
Dialysis 10,352 16 (0.2) 14 (0.2) 2 (0.3) 0.64
Cancer 10,388 845 (8.1) 740 (7.7) 105 (14.1) <0.001
Obstructive Sleep Apnea Syndrome 10,337 654 (6.3) 524 (5.5) 130 (17.6) <0.001
Dependency status
Independent 10,250 8519 (83.1) 7960 (83.7) 559 (76.7) –
Moderate dependency 984 (9.6) 856 (9.0) 128 (17.4) <0.001
Severe dependency 747 (7.3) 700 (7.4) 47 (6.4) 0.76
Charlson Comorbidity Index 10,084 1 (0–2) 1 (0–2) 2 (1–4) <0.001
Charlson Comorbidity Index, age corrected 10,048 3 (1–5) 3 (1–5) 6 (4–8) <0.001
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Table 2 Characteristics of People with Coronavirus Disease 2019 with or without COPD. Clinical Data and Evolution
Characteristics Values are Indicated as the Number (Percentage) or Median (Interquartile Range)
Overall (n=10,420) N (%) Non-COPD (n=9674) COPD (n=746) P value
Habitual treatment
Immunosuppressants 10,383 362 (3.5) 335 (3.5) 27 (3.6) 0.82
Systemic corticosteroids 10,392 450 (4.3) 395 (4.0) 55 (7.4) <0.001
Inhaled corticosteroids 10,340 1031 (10.0) 683 (7.1) 348 (47.2) <0.001
Anticoagulants
None 10,338 9148 (88.5) 8582 (89.4) 566 (76.4) -
Antivitamin K 653 (6.3) 552 (5.8) 101 (13.6) <0.001
DOACs 456 (4.4) 388 (4.0) 68 (9.2) <0.001
LMWH 81 (0.8) 75 (0.8) 6 (0.8) 0.65
Antiplatelet drugs 10,319 1591 (15.4) 1393 (14.5) 198 (26.9) <0.001
Statins 10,319 3302 (32.0) 2928 (30.6) 374 (50.6) <0.001
ACE inhibitors 10,330 1757 (17.0) 1590 (16.6) 167 (22.6) <0.001
Angiotensin-renin blockers 10,334 2014 (19.5) 1829 (19) 185 (25) <0.001
Symptoms and vital signs
Temperature >38 ºC 10,369 6581 (63.5) 6181 (64.2) 400 (53.8) <0.001
Low-grade fever 10,369 2195 (21.2) 2025 (21) 170 (22.9) <0.001
Dyspnea 10,369 5939 (53.4) 5402 (56.2) 537 (72.3) <0.001
Dry cough 10,368 6084 (58.7) 5724 (59.5) 360 (48.5) <0.001
Cough with expectoration 1652 (15.9) 1452 (15.1) 200 (26.9) <0.001
Fatigue 10,157 4493 (44.2) 4193 (44.5) 300 (41.2) 0.088
Anorexia 10,102 2045 (20.2) 1903 (20.3) 142 (19.6) 0.68
Myalgia 10,198 3146 (30.9) 2969 (31.4) 177 (24.2) <0.001
Headache 10,160 1192 (11.7) 1152 (12.2) 40 (5.5) <0.001
Diarrhea 10,287 2339 (22.7) 2239 (23.5) 100 (13.6) <0.001
Nausea 10,121 1274 (12.6) 1233 (13.1) 41 (5.7) <0.001
Vomiting 10,249 759 (7.4) 740 (7.8) 19 (2.6) <0.001
Abdominal pain 10,235 683 (6.7) 649 (6.8) 34 (4.6) 0.022
Ageusia 9971 656 (6.6) 632 (6.8) 24 (3.4) <0.001
Anosmia 9967 584 (5.9) 563 (6.1) 21 (3.0) 0.001
Sore throat 10,147 994 (9.8) 926 (9.8) 68 (9.4) 0.68
Vital signs at triage
Temperature >38 °C 9978 1611 (16.2) 1516 (16.4) 95 (13.3) 0.029
Temperature, median (IQR) ºC 9978 37 (36.4–37.8) 36.9 (36.2–37.7) 37 (36.4–37.8) 0.004
Sat <90% 10,084 2211 (21.9) 1928 (20.6) 283 (38.8) <0.001
Sat02% Median (IQR) 10,084 94 (91–97) 95 (91–97) 92 (88–95) <0.001
Respiratory rate >20 breaths/min 10,097 3145 (31.2) 2797 (29.9) 348 (47.9) <0.001
Heart rate >100 beats/min 9990 2181 (21.8) 2036 (22.0) 145 (20.0) 0.22
Heart rate Median (IQR) 9990 87 (76–100) 87 (76–100) 85 (75–98) 0.08
SBP, median (IQR) mmHg 9870 127 (114–141) 127 (115–140) 127 (113–144) 0.96
DBP, median (IQR) mmHg 9860 74 (65–82) 74 (65–82) 72 (61–80) <0.001
Confusion 10,270 1227 (12.0) 1100 (11.5) 127 (17.3) <0.001
Wheezing 10,105 625 (6.2) 501 (5.3) 124 (17.3) <0.001
Rhonchi 10,097 1088 (10.8) 890 (9.5) 198 (27.6) <0.001
Crackles 10,107 5324 (52.7) 4937 (52.6) 387 (53.9) 0.49
Evolution
Non-invasive mechanical ventilation 10,327 503 (4.9) 429 (4.5) 74 (10.1) <0.001
High-flow nasal cannula 10,264 832 (8.1) 736 (7.7) 96 (13.2) <0.001
(Continued)
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infarction and obesity. Associating the comorbidities in 
clusters: risk factors, neurological, cardiovascular, hepatic- 
renal and oncological, we found that cardiovascular and 
hepatic-renal were associated with an increase in mortality 
in COPD patients with COVID. COPD patients with SARS- 
CoV2 infection who presented some comorbid pathology 
had higher mortality than those who did not have any 
comorbidity (Table 5).
Higher all-cause mortality was observed in patients in 
regular treatment with systemic corticosteroids and in patients 
who were anticoagulated and antiaggregated with acetylsa-
licylic acid, which could possibly reflect increased cardiovas-
cular disease. However, neither chronic treatment with ACE 
inhibitors nor with angiotensin-renin blockers were asso-
ciated with higher all-cause mortality in this population.
We found no differences in survival in COPD patients 
among current smokers, former smokers, and never smo-
kers (Figure 1). A worse FEV1 value also did not correlate 
with mortality.
In regard to hemogram parameters, all- cause mortality 
was associated with higher levels of leukocytes (7180 vs 
6400, p 0.002), neutrophils (5125 vs 4640, p 0.004), 
C-reactive protein (CRP) (99.2 vs 63.9, p<0.001), creati-
nine (1.21 vs 1.0, p 0.001), lactate dehydrogenase (LDH) 
(352 vs 270, p<0.001), procalcitonin (0.2 vs 0.1, p 0.003), 
and D-Dimer (1014 vs 695, p 0.002).
Radiologically, the presence of bilateral condensation, 
bilateral interstitial infiltrates, and radiological worsening at 
one week was associated with an increased mortality rate.
In terms of treatment, 56.9% of COPD patients received 
treatment with lopinavir/ritonavir and 49% received sys-
temic corticosteroids; greater survival was not observed 
among these patients. Survival was higher among patients 
with COPD who were treated with hydroxychloroquine 
(87.1% vs 74.9%, p<0.001) and with macrolides (57.9% 
vs 50%, p<0.037). An improved prognosis was not 
observed with the use of beta-lactams or quinolones. 
Neither prone positioning, non-invasive mechanical venti-
lation, high-flow nasal cannula, or invasive mechanical 
ventilation were associated with a better prognosis.
Discussion
This is the first work that describes the characteristics 
and prognosis of COPD patients hospitalized with 
SARS-CoV-2 infection.
One of the most notable findings among these data is the 
low prevalence of COPD patients. Given that COVID-19 is 
a viral disease with respiratory involvement, it would be 
logical to expect to find a higher percentage of COPD 
patients. In previous works, the incidence of COPD in 
patients hospitalized with COVID-19 has been estimated 
to be 0.95%3 and the prevalence of patients with COVID-19 
who had COPD has been estimated to be 2%.10 In pre-
viously published data from the SEMI-COVID-19 registry, 
the incidence of COPD was 7.7%.12 The prevalence found 
in our registry is higher than in the New York area series 
(5.4%), but lower than some of the Chinese series.13
One of the reasons can explain the low prevalence of 
COVID-19 among COPD patients could be the use of 
drugs for respiratory disease like inhaled steroids, beta- 
agonists or anticholinergics, specially tiotropium.14 In the 
other side, glycopyrronium and formoterol have been 
shown to reduce cellular susceptibility to coronavirus 
infection in vitro. They do so by inhibiting the expression 
of coronavirus receptors, reducing endosomal activity, and 
modulating the inflammatory responses induced by it in 
the airway. Indeed, basic treatment for COPD patients 
usually includes long-acting muscarinic antagonists 
(LAMA) and/or long-acting b2-agonists (LABA).15 
Based on this low prevalence, it could be said that 
COPD patients would not have an increased risk of con-
tracting SARS-CoV2 infection. These data are taken from 
hospitalized patients, and to be able to affirm these results 
Table 2 (Continued). 
Characteristics Values are Indicated as the Number (Percentage) or Median (Interquartile Range)
Overall (n=10,420) N (%) Non-COPD (n=9674) COPD (n=746) P value
Invasive mechanical ventilation 10,326 663 (6.4) 627 (6.5) 36 (4.9) 0.083
Prone position 10,307 1020 (9.9) 938 (9.8) 82 (11.2) 0.21
ICU admission 10,400 841 (8.1) 788 (8.2) 53 (7.1) 0.31
Hospital stay in days, median (IQR) 9 (5–14) 9 (5–14) 10 (6–16) 0.80
Mortality 2142 (20.6) 1856 (19.2) 286 (38.3) <0.0001
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we would also need to have data from non-hospitalized 
COPD patients.
However, COPD patients with COVID-19 have a poor 
prognosis. COPD patients are older and have more 
comorbidities, especially cardiovascular comorbidities. 
This association between COPD and comorbidity has pre-
viously been described, especially in patients hospitalized 
for an exacerbation, which is an important prognostic 
Table 3 Mortality of COPD Patients with Coronavirus Disease 2019 According to Demographic Data and Antecedents
Values are Indicated as the Number (Percentage) or Median (Interquartile Range)
Characteristics Overall (n=746) Survivors (n=460) Deceased (n=286) Odds Ratio (95% CI) P value
Age (years) 77 (71–84) 75 (66–82) 79 (74–86) 1.06 (1.04–1.08) <0.001
Men 612 (82.2) 365 (79.4) 247 (86.7) 1.69 (1.12–2.55) 0.012
Comorbidities
FEV1
<30 21 (5.8) 11 (4.9) 10 (7.3) 1.74 (0.58–5.26) 0.33
30–49 84 (23.1) 52 (22.9) 32 (23.4) 1.18 (0.52–2.69) 0.70
50–79 224 (61.5) 141 (62.1) 83 (60.6) 1.13 (0.53–2.39) 0.75
≥80 35 (9.6) 23 (10.1) 12 (8.8) Ref. (1) -
FEV1 <50 105 (28.8) 63 (27.8) 42 (30.7) 1 (ref.) -
FEV1 >50 259 (71.2) 164 (72.2) 95 (69.3) 0.87 (0.55–1.38) 0.55
Smoking status
Never 107 (14.8) 59 (13.3) 48 (17.0) 1 (ref.) -
Former 514 (70.7) 316 (71.0) 198 (70.2) 0.77 (0.51–1.17) 0.22
Current 106 (14.6) 70 (15.7) 36 (12.8) 0.63 (0.36–1.1) 0.12
Obesity (BMI>30) 122 (32.1) 73 (30.7) 49 (34.5) 1.19 (0.77–1.85) 0.44
Hypertension 513 (69.1) 298 (65.0) 215 (75.7) 1.67 (1.2–2.3) 0.002
Hyperlipidemia 396 (53.4) 239 (52.2) 157 (55.3) 1.13 (0.84–1.52) 0.41
Diabetes mellitus 191 (25.8) 119 (26.1) 72 (25.4) 0.96 (0.69–1.35) 0.82
Atrial fibrillation 175 (23.6) 103 (22.5) 72 (25.4) 1.18 (0.83–1.66) 0.36
Myocardial infarction 98 (13.2) 52 (11.3) 46 (16.1) 1.51 (0.98–2.32) 0.059
Heart failure 132 (17.8) 58 (12.7) 74 (26.1) 2.43 (1.65–3.56) < 0.001
Transient ischemic attack 90 (12.2) 48 (10.5) 42 (15.1) 1.52 (0.97–2.37) 0.066
Dementia 79 (10.6) 36 (7.8) 43 (15.0) 2.08 (1.3–3.33) 0.002
Neurodegenerative disease 71 (9.5) 34 (7.4) 37 (12.9) 1.85 (1.13–3.03) 0.014
Peripheral arterial disease 89 (12.0) 51 (11.1) 38 (13.4) 1.24 (0.79–1.94) 0.35
Chronic kidney disease 82 (11.0) 41 (8.9) 41 (14.4) 1.71 (1.08–2.72) 0.022
Cancer 105 (14.1) 60 (13.1) 45 (15.8) 1.25 (0.82–1.89) 0.30
Obstructive Sleep Apnea Syndrome 130 (17.6) 83 (18.1) 47 (16.9) 0.92 (0.62–1.34) 0.66
Dependency status
Independent 559 (76.2) 377 (82.7) 182 (65.5) 1 (ref.) -
Moderate dependency 128 (17.4) 61 (13.4) 67 (24.1) 2.28 (1.54–3.36) < 0.001
Severe dependency 47 (6.4) 18 (4.0) 29 (10.4) 3.34 (1.81–6.17) < 0.001
Charlson Comorbidity Index 2 (1–4) 2 (1–4) 3 (2–5) 1.17 (1.09–1.26) < 0.001
Charlson Comorbidity Index, age corrected 6 (4–8) 5 (4–7) 6 (5–9) 1.23 (1.15–1.32) < 0.001
Habitual treatment
Immunosuppressants 27 (3.6) 19 (4.1) 8 (2.8) 0.68 (0.29–1.56) 0.36
Systemic corticosteroids 55 (7.4) 27 (5.9) 28 (9.9) 1.75 (1.01–3.04) 0.046
Inhaled corticosteroids 348 (47.2) 216 (47.2) 132 (47.1) 1 (0.74–1.35) 0.996
Antivitamin K 101 (13.6) 48 (10.5) 53 (18.7) 1.94 (1.27–2.98) 0.002
Antiplatelet Drugs 198 (26.9) 105 (23.0) 93 (33.2) 1.67 (1.20–2.32) 0.002
Statins 374 (50.6) 237 (51.8) 137 (48.8) 0.89 (0.66–1.19) 0.43
ACE In 167 (22.6) 101 (22.1) 66 (23.5) 1.09 (0.76–1.54) 0.65
Angiotensin-renin blockers 185 (25) 107 (23.3) 78 (27.7) 1.26 (0.90–1.77) 0.19
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factor. Almagro confirmed the elevated prevalence of asso-
ciated diseases in patients with COPD who are admitted to 
the Spanish Internal Medicine Services; in a later article he 
showed that mortality at 3 months in hospitalized COPD 
patients was associated with comorbidities both measured 
with the Charlson index and total of comorbidities.2,16 
Roberts demonstrated that comorbidities adversely affect 
in hospitalized COPD exacerbations.17 Alqahtani in 
a systematic review and meta-analysis found that heart 
failure, renal failure, depression and alcohol use were all 
associated with an increased risk of 30-day all-cause 
readmission.18 The association between comorbidities 
Table 4 Mortality of COPD Patients with Coronavirus Disease 2019 According to Clinical Data and Treatment
Values are Indicated as the Number (Percentage) or Median (Interquartile Range)
Characteristics Overall (n=746) Survivors (n=460) Deceased (n=286) Odds Ratio (95% CI) P value
Symptoms and vital signs
Dyspnea 537 (72.3) 304 (66.1) 233 (82.3) 2.39 (1.67–3.43) <0.001
Temperature >38 ºC 95 (13.3) 47 (10.6) 48 (17.5) 1.78 (1.15–2.74) 0.009
Oxygen saturation <90% 283 (38.8) 131 (29.1) 152 (54.3) 0.35 (0.25–0.47) <0.001
Oxygen saturation % Median (IQR) 92 (88–95) 93 (90–96) 90 (86–94) 0.91 (0.88–0.93) <0.001
Respiratory rate >20 breaths/min 348 (47.9) 169 (37.6) 179 (64.6) 3.03 (2.22–4.13) <0.001
Heart rate
>100 beats/min 145 (20.0) 80 (17.9) 65 (23.4) 1.40 (0.97–2.02) 0.073
Median (IQR) 85 (75–98) 85 (74–98) 86 (76–100) 1.01 (0.99–1.01) 0.18
SBP, median (IQR) mmHg 127 (113–144) 129 (116–144) 125 (110–141) 0.99 (0.99–1) 0.09
DBP, median (IQR) mmHg 72 (61–80) 73 (64–81) 70 (60–80) 0.99 (0.98–0.99) 0.008
Confusion 127 (17.3) 53 (11.7) 74 (26.3) 2.71 (1.83–4) <0.001
Radiological findings
At admission
Bilateral condensation 203 (27.7) 107 (23.7) 96 (33.9) 1.8 (1.29–2.6) 0.001
Bilateral interstitial infiltrates 359 (48.9) 202 (44.7) 157 (55.7) 1.6 (1.13–2.15) 0.006
Progress (7 days)
Bilateral condensation 198 (36.5) 114 (30.7) 84 (49.1) 2.38 (1.58–3.57) < 0.001
Bilateral interstitial infiltrates 316 (58.1) 201 (53.9) 115 (67.3) 1.55 (1.03–2.32) 0.035
Radiological worsening 277 (50.8) 147 (39.6) 130 (74.7) 4.5 (3.02–6.72) < 0.001
Treatment
Lopinavir/ritonavir 421 (56.9) 267 (58.4) 154 (54.4) 0.85 (0.63–1.45) 0.29
Interferon-beta 94 (12.8) 41 (9.0) 53 (19.0) 2.36 (1.52–3.66) < 0.001
Remdesivir 4 (0.6) 2 (0.4) 2 (0.7) 1.66 (0.23–11.85) 0.61
Hydroxychloroquine 610 (82.4) 398 (87.1) 212 (74.9) 0.44 (0.3–0.65) < 0.001
Chloroquine 26 (3.5) 16 (3.5) 10 (3.6) 1.02 (0.46–2.29) 0.96
Colchicine 10 (1.4) 4 (0.9) 6 (2.2) 2.5 (0.7–8.9) 0.16
Tocilizumab 50 (6.8) 23 (5.0) 27 (9.6) 1.99 (1.12–3.56) 0.019
Immunoglobulin 2 (0.3) 1 (0.2) 1 (0.4) 1.7 (0.1-26-6) 0.72
Anakinra 4 (0.6) 3 (0.7) 1 (0.4) 0.54 (0.06–5.24) 0.60
Systemic corticosteroids 364 (49.3) 215 (47.1) 149 (53.0) 1.27 (0.94–1.71) 0.12
Beta-lactams 561 (76.3) 329 (72.3) 232 (82.9) 1.85 (1.28–2.69) 0.001
Macrolides 400 (55.0) 263 (57.9) 137 (50.0) 0.73 (0.54–0.98) 0.037
Quinolones 134 (18.5) 78 (17.2) 56 (20.5) 1.24 (0.85–1.82) 0.27
Non-invasive mechanical ventilation 74 (10.1) 34 (7.5) 40 (14.4) 2.09 (1.29–3.40) 0.003
High-flow nasal cannula 96 (13.2) 46 (10.2) 50 (18.0) 1.93 (1.25–2.97) 0.003
Invasive mechanical ventilation 36 (4.9) 8 (1.8) 28 (10.1) 6.27 (2.82–13.97) <0.001
Prone position 82 (11.2) 25 (5.5) 57 (20.6) 4.44 (2.70–7.29) <0.001
Hospital stay in days, median (IQR) 10 (6–16) 12 (7–17) 7 (3–12) 0.95 (0.93–0.96) <0.001
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and the severity of SARS-CoV-2 infection has also been 
described, finding that greater severity is correlated with 
increased comorbidity. Thus, the presence of two or more 
comorbidities was observed more frequently in severe 
cases than in non-severe cases (40.0% vs 29.4%).4 In our 
work, the Charlson Comorbidity Index, a comorbidity 
index that has been validated as a prognostic factor in 
COPD, is also associated with a worse prognosis in 
patients with COVID-19. Although obesity is considered 
a risk factor in COVID, in our work it is not related to 
mortality in COPD patients.19 This may be justified by 
a protective effect of obesity on all-cause mortality in 
COPD patients, described in several studies. This protec-
tion is more evident for subjects with a lower FEV1.20 
Several mechanisms have been proposed that may explain 
why COVID-19 is more frequent in male patients, elderly 
with multimorbidity. The higher incidence in men may be 
associated with the fact that androgen receptor activity is 
required for the transcription of the TMPRSS2 gene.
In old age there is multisystem dysregulation with 
a reduced physiological reserve and a poor immune 
response. In an aging immune system there is a chronic 
low systemic inflammatory state with elevated levels of 
IL-6 and C-reactive protein and increased susceptibility to 
infection. In diabetes there is a low-grade systemic inflam-
mation, which can facilitate a greater release of cytokines 
and an altered immune response after infection. The pan-
creas expresses ECA2, through which the coronavirus can 
Table 5 Comorbidity and mortality of COPD Patients with Coronavirus Disease 2019
Characteristics Overall (n=746) Survivors (n=460) Deceased (n=286) Odds Ratio (95% CI) P value
Comorbidity - CVRFa
No 169 (22.6) 111 (24.1) 58 (20.3) 1 (ref.) –
Yes 577 (77.4) 349 (75.9) 228 (79.7) 1.25 (0.87–1.79) 0.22
Comorbidity - NRLb
No 583 (78.2) 373 (81.1) 210 (73.4) 1 (ref.) –
Yes 163 (21.9) 87 (18.9) 76 (26.6) 1.55 (1.09–2.20) 0.014
Comorbidity - Cardioc
No 406 (54.4) 266 (57.8) 140 (49.0) 1 (ref.) –
Yes 340 (45.6) 194 (42.2) 146 (52.0) 1.43 (1.06–1.92) 0.018
Comorbidity – K.Ld
No 614 (82.3) 387 (84.1) 227 (79.4) 1 (ref.) –
Yes 132 (17.7) 73 (15.9) 59 (20.6) 1.38 (0.94–2.02) 0.10
Comorbidity - Oncoe
No 623 (83.5) 392 (85.2) 231 (80.8) 1 (ref.) –
Yes 123 (16.5) 68 (14.8) 55 (19.2) 1.37 (0.93–2.03) 0.11
Comorbidityf
No 64 (8.6) 51 (11.1) 13 (4.5) 1 (ref.) –
Yes 682 (91.4) 409 (88.9) 273 (95.5) 2.62 (1.40–4.91) 0.003
Notes: aComorbidity-CVRF: Considering as comorbidity the presence of any of the following Cardiovascular Risk Factors: HBP, Dyslipidemia, Diabetes Mellitus (with or 
without target organ injury) or Obesity. bComorbidity-NRL: We consider as comorbidity the presence of any of the following pathologies: Dementia, Neurodegenerative 
disease, Transient ischemic attack, Acute cerebrovascular accident, Hemiplegia. cComorbidity-Cardio: We consider as comorbidity the presence of any of the following 
pathologies: Atrial fibrillation, myocardial infarction, Angor, CHF, Peripheral vascular disease. dComorbidity-K.L: We consider as comorbidity the presence of any of the 
following pathologies: chronic kidney disease or Hemodialysis, mild or moderate–severe chronic liver disease. eComorbidity-Onco: We consider as comorbidity the 
presence of any of the following pathologies: solid neoplasia with or without metastasis, leukemia or lymphoma. fComorbidity: In this case we consider as comorbidity the 
presence of any of the pathologies included in the previous ones.
Figure 1 Mortality according to smoking status in COPD with COVID-19.
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enter the islets and cause acute B-cell dysfunction, leading 
to acute hyperglycemia. Many of the poor prognostic 
comorbidities of COViD-19 share insulin resistance. 
Multimorbidity is also associated with elevated plasmino-
gen levels. Plasmin and other proteases can cleave a newly 
inserted furin site in the SARS-CoV-2 protein S, increas-
ing its infectivity and virulence.21
Some coronaviruses have been associated with exacer-
bations of COPD, but neither MERS-CoV nor SARS-CoV 
-1 showed this association.22,23 The presentation of 
COVID-19 in patients with COPD has been described as 
different from an exacerbation of COPD, since they pre-
sent with flu-like symptoms such as fever, anorexia, myal-
gia, and gastrointestinal symptoms.24 However, in the 
patients analyzed in this study, the usual presentation 
included increased dyspnea and expectoration and the 
presence of rhonchi and wheezing on auscultation, similar 
to a normal infectious exacerbation. Based on this, we 
recommend performing a SARS-CoV-2 test in all COPD 
patients with symptoms of exacerbation.
In our series, as in others, COPD patients hospitalized 
for COVID-19 have a high mortality rate and COPD is 
considered a predictor of poor prognosis. In the work by 
Wang et al, patients with COPD were found to be 5.9 
times more at risk of suffering severe forms of COVID- 
19 than patients without COPD.25 In the work by Zhao 
et al, the presence of COPD entailed a four-fold risk of 
suffering a serious course of COVID-19.9 Alqahtani et al 
indicate that the presence of COPD increased the risk of 
severe coronavirus, with a RR of 1.88. They found that 
63% of patients with COPD developed severe forms of the 
disease compared to 33.4% of those without COPD, with 
a mortality rate of 60% among patients with COPD.10 In 
patients older than age 60 who are diagnosed with 
COVID-19, COPD was a predictor of death, (OR 
2.24).26 In a meta-analysis, COPD was associated with 
an increased mortality risk, (OR 3.53).27 In the work by 
Lippi, COPD was significantly associated with severe 
COVID-19, OR: 5.69.28 COPD has also been described 
as a risk factor for disease progression (HR 2.01, 95% CI 
1.38–2.93).29 It is possible that poor prognosis depends 
only on the COPD itself or it may be partially associated 
with the multimorbidity of these patients.
Smokers are at higher risk of contracting respiratory 
tract infections such as influenza, and that these are more 
serious, as in the previous MERS outbreak where smokers 
had a higher mortality. A low prevalence of smoking has 
been found in COVID-19 cases, although published data 
on the severity of COVID-19 in smokers is variable. In 
a meta-analysis, active smokers were found to be 1.45 
times more likely to have serious complications compared 
to ex-smokers and those who had never smoked. They also 
had a higher mortality rate of 38.5%. In another work, the 
combined OR was 2.20. However, in other studies, the 
association between active smoking and severe COVID-19 
was not found to be significant. It has even been reported 
that smoking may be associated with a non-significant 
trend towards decreased severity of the disease and per-
haps even a protective factor against disease progression 
(HR 0.56, 95% CI 0.34 at 0.91). Vardavas in a systematic 
review of studies concludes that it is very likely that 
smoking is associated with poor progression and poor 
prognosis of COVID-19.
It has been postulated that the infection is more severe 
in patients with COPD and in smokers because exposure to 
tobacco causes an alteration in the regulation of ACE-2 
expression, these patients presenting an overexpression of 
ACE-II, the receptor of the virus to enter the cell; further-
more, the expression levels of ACE-II are inversely related 
to FEV1. However, in our study, the smoking status has not 
been related to all-cause mortality. It is also proposed that in 
smokers the immune system is impaired, with an altered 
response of macrophages and cytokines, and the inflamma-
tory cascade that occurs in SARS-CoV-2 infection could be 
especially catastrophic. Another hypothesis is that nicotine 
may have a protective effect on COVID-19, which disap-
pears due to the abrupt cessation of nicotine intake when 
smokers are hospitalized.5,9,10,29–34
Classically, mortality in COPD has been associated with 
FEV1. It is now known that its predictive value is low when 
it is greater than 50% of what was expected and that there 
are other clinical variables that predict mortality better than 
FEV1, as reflected in the different multicomponent prog-
nostic indices in COPD. In our work, no association was 
found between FEV1 and all-cause mortality.35,36
Scientific societies advise maintaining the usual treat-
ment and management of exacerbation in COPD patients 
according to current recommendations. The best way to 
prevent and reduce the severity of exacerbations in respira-
tory infections in patients with COPD is optimal drug 
treatment. There is no evidence that inhaled corticosteroids 
increase the risk of or worsen SARS-CoV-2 infection. In 
an exacerbation of COPD with concurrent SARS-CoV-2 
infection, it is advisable to follow the indications for 
treatment with corticosteroids recommended in the guide-
lines, although efforts should be made to limit the dose and 
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duration of the corticosteroids due to the possibility of 
increasing viral replication.37,38
In our work, COPD patients who were in regular 
treatment with systemic corticosteroids had a higher mor-
tality rate. This could possibly be a reflection of more 
severe COPD with worse functional capacity in addition 
to possible immunosuppression associated with the use of 
systemic corticosteroids, which would entail a higher viral 
load and greater SARS-CoV-2 involvement.
A better prognosis was not found in patients treated 
with lopinavir/ritonavir or systemic corticosteroids. The 
study by Cao et al also found no benefits in the use of 
lopinavir/ritonavir in hospitalized patients with severe 
COVID-19 pneumonia, although the study was probably 
underpowered.39
We found a higher survival rate in patients treated with 
hydroxychloroquine and with macrolides. Azithromycin is 
frequently used for exacerbations of COPD, but it has 
emerged as a possible complementary therapy with hydro-
xychloroquine for COVID-19. Azithromycin has immuno-
modulatory activity and, presumably, antiviral activity. 
Hydroxychloroquine would have activity at various levels: 
on the one hand, it acts through ACE2, attenuating the entry 
of SARS-CoV-2 into the pulmonary epithelium and, on the 
other hand, it can have immunosuppressive effects by redu-
cing IL-6 production in T cells and monocytes. Caution is 
advised in trials evaluating azithromycin along with hydro-
xychloroquine for its effects on QT segment prolongation 
and propensity for arrhythmias.40–42 Regarding hydroxy-
chloroquine, our study is not designed to verify its usefulness 
in treatment and at present, its use is only recommended in 
clinical trials. Further studies are required to determine the 
usefulness of azithromycin and/or hydroxychloroquine treat-
ment in COPD patients with SARS-CoV-2 infection.
SARS-COv2 infection produces immunosuppression 
with lymphopenia, suppression of interferon, and defective 
NK cell function. This loss of the antiviral defense 
mechanism can activate a more aggressive “second 
wave” of immunity, with a cytosine storm, with very 
high levels of ferritin, C-reactive protein and IL-1β, IL-2, 
IL-6, IL −17, IL-8 and TNF. We also found an elevated 
D-dimer as a representation of the extension of this hyper-
inflammatory state to the adjacent microcirculation with 
secondary fibrinolytic activation that would be associated 
with extensive pulmonary microthrombosis. This immune 
hyperactivity is more confined to the lung parenchyma and 
adjacent bronchial alveolar lymphoid tissue and is asso-
ciated with the development of an acute respiratory 
distress syndrome that may require ventilatory support. 
This condition is similar to the macrophage activation 
syndrome seen in some systemic diseases, but located in 
the lung, which is not usually accompanied by organome-
galy or disseminated intravascular coagulation. Anti-IL-6 
and anti-IL-1 medications are being used to prevent this. 
In our study, however, so few patients were treated with 
tocilizumab or anakinra that no conclusions or recommen-
dations can be drawn.43–47
With the data we have so far and given the severity of 
COVID-19, it may be necessary to consider combination 
treatment for COPD patients with action at two levels: one 
to avoid the binding of SARS-CoV-2 to lung tissue and 
another that blocks the cytokine storm that is released.47
This work has several limitations. First, the data 
included in the registry are collected by a large team of 
researchers. Second, many patients have a history of COPD, 
but spirometric data are not always included and as such, 
the registry could include patients who have not been prop-
erly diagnosed of COPD. Third, 26% of non-COPD patients 
reported being smokers or ex-smokers. Taking into account 
the underdiagnosis of COPD in the population, it is logical 
to assume that the prevalence of patients with COPD is 
higher. Lastly, in the SEMI-COVID registry, data on 
chronic treatment with inhalers were not included, so we 
have not been able to analyze if LAMA and/or LABA could 
have a protective effect on SARS-CoV-2 lung infection.15
Conclusion
Although patients with COPD do not seem to have 
a higher risk of contracting SARS-CoV-2 infection, they 
do have a worse prognosis, especially in patients with 
greater comorbidity. These patients must be identified 
early in order to establish preventive measures that reduce 
risk and provide adequate management.
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